GlaxoSmithKline (GSK) is expanding its campus in Barnard Castle in the United Kingdom with the construction of a $130 million liquid biopharmaceuticals production plant. The 124,000-sf aseptic sterile facility will make injectable liquids for the treatment of respiratory and autoimmune diseases and is slated for completion by November of 2019. Building Information Modeling (BIM) and offsite construction methodologies are being implemented in the delivery of the project, which includes the specification that the building can be replicated anywhere in the world. The MEP engineer for the facility is SES Engineering Services. Additionally, GSK is building a $200 million pharmaceutical manufacturing center in Marburg, Germany, which is slated for completion in late 2020.
